07:47 AM EDT, 09/23/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Tuesday that a phase 3 trial assessing its investigational therapy iberdomide combined with standard therapies showed "statistically significant improvement" in minimal residual disease negativity rates in patients with relapsed or refractory multiple myeloma.

Minimal residual disease refers to any cancer cells remaining in a patient's body following treatment and is used to gauge treatment response, the company said.

The trial, testing iberdomide in combination with daratumumab and dexamethasone, will continue evaluating the other dual-primary endpoint of progression-free survival and the secondary endpoint of overall survival and safety, Bristol-Myers Squibb ( BMY ) added.